Research
Hormonal
Achieving comprehensive metabolic control (simultaneous HbA1c, LDL-C, and blood pressure targets) significantly reduces the risk of cardiovascular and microvascular complications in diabetic patients.
For diabetic patients, managing blood sugar, blood pressure, and cholesterol together is critical. Missing any one target leaves you at higher risk for heart and kidney damage. Work with your doctor to hit all three goals simultaneously, not just one.
GoodSupportsHIGH confidence
good metabolic control was associated with a reduction in cardiovascular events (p = 0.013; OR = 0.22; 95% CI [0.19 - 0.28]) and microvascular complications (p = 0.001; OR = 0.31; 95% CI [0.26 - 0.43]).
Why this rating
Prospective observational study with a large sample size (n=771) and long follow-up (2 years), though not a randomized controlled trial.
Source
Optimizing Diabetes Management: Insights from a Prospective Study
Loubna Saadaoui et al. · Case Reports in Clinical Medicine · 2026
DOI 10.4236/crcm.2026.152007
cohort · n=771
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →